Immunoprecise Stock Valuation

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Do you wonder what the value of Immunoprecise Antibodies is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Immunoprecise Antibodies, is its stock price multiplied by the total number of shares outstanding, calculating Immunoprecise Antibodies' enterprise value requires a different approach. It uses Immunoprecise Antibodies' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
The current year Tangible Asset Value is expected to grow to about 65.9 M, whereas Free Cash Flow is forecasted to decline to (2.5 M).
Immunoprecise Antibodies retains a regular Real Value of $6.72 per share. The prevalent price of the firm is $5.3. At this time, the firm appears to be undervalued. Our model calculates the value of Immunoprecise Antibodies from evaluating the firm fundamentals such as Current Valuation of 78.03 M, return on equity of (42.77) %, and Return On Asset of (18.66) % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage taking in undervalued assets and trading overvalued assets since, at some point, asset prices and their ongoing real values will come together.
  
Refresh
Immunoprecise Antibodies Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Immunoprecise Antibodies's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 5.30
Share
Please note that Immunoprecise Antibodies' price fluctuation is moderately volatile at this time. Calculation of the real value of Immunoprecise Antibodies is based on 3 months time horizon. Increasing Immunoprecise Antibodies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Immunoprecise Antibodies is useful when determining the fair value of the Immunoprecise stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Immunoprecise Antibodies. Since Immunoprecise Antibodies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunoprecise Stock. However, Immunoprecise Antibodies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
6.72
Real Value
11.44
Upside
Estimating the potential upside or downside of Immunoprecise Antibodies helps investors to forecast how Immunoprecise stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunoprecise Antibodies more accurately as focusing exclusively on Immunoprecise Antibodies' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.604.966.32
Details
Hype
Prediction
LowEstimated ValueHigh
0.675.3910.11
Details
Naive
Forecast
LowNext ValueHigh
1.175.8910.60
Details
1 Analysts
Consensus
LowTarget PriceHigh
12.0012.0012.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immunoprecise Antibodies' intrinsic value based on its ongoing forecasts of Immunoprecise Antibodies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immunoprecise Antibodies' closest peers. When choosing an evaluation method for Immunoprecise Antibodies, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Immunoprecise Antibodies Investments

129,016

Share

Immunoprecise Valuation Drivers Correlation

Many accounts on the financial statements of Immunoprecise Antibodies are highly interrelated and sometimes correlated. Consequently, when conducting Immunoprecise's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Immunoprecise
Click cells to compare fundamentals

Immunoprecise Valuation Trend

Knowing Immunoprecise Antibodies' actual value is paramount for traders to make sound investment determinations. Immunoprecise Antibodies' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Immunoprecise Antibodies' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Immunoprecise Antibodies' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Immunoprecise Market Cap

Immunoprecise Antibodies is rated second overall in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 457.75 Million. Immunoprecise Antibodies totals roughly 102.98 Million in market capitalization claiming about 23% of stocks in Biotechnology industry.
Capitalization  Workforce  Revenue  Valuation  Total debt

Immunoprecise Antibodies Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunoprecise Antibodies competition to find correlations between indicators driving Immunoprecise Antibodies's intrinsic value. More Info.
Immunoprecise Antibodies is rated second overall in price to sales category among related companies. It is currently regarded as number one stock in price to book category among related companies fabricating about  0.37  of Price to Book per Price to Sales. The ratio of Price to Sales to Price to Book for Immunoprecise Antibodies is roughly  2.68 . As of May 28, 2022, Price to Book Value is expected to decline to 3.19. Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunoprecise Antibodies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunoprecise Antibodies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Immunoprecise Antibodies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Immunoprecise Antibodies and how it compares across the competition.

About Immunoprecise Antibodies Valuation

The equity valuation mechanism determines the current worth of Immunoprecise Antibodies on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Immunoprecise Antibodies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Immunoprecise Antibodies based exclusively on its fundamental and basic technical indicators. By analyzing Immunoprecise Antibodies's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Immunoprecise Antibodies's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Immunoprecise Antibodies. We calculate exposure to Immunoprecise Antibodies's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Immunoprecise Antibodies's related companies.
Last ReportedProjected for 2022
Gross Profit13.3 M11.8 M
Profit Margin(0.47) (0.51) 
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing B cell sorting, screening, and sequencing custom, immune, and naive phage display production and screening transgenic animals and multi-species antibody discovery bi-specific, tri-specific, VHH, and VNAR antibody manufacturing DNA cloning, protein and antibody downstream processing antibody characterization on label-free biosensors and antibody engineering transient and stable cell line generation antibody optimization and humanization hybridoma production with multiplexed, high-throughput screening, and clone-picking and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Immunoprecise Antibodies Quarterly Enterprise Value

91.99 Million

Share

Immunoprecise Antibodies Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Immunoprecise Antibodies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio5.10
Revenue Growth6.60%
Enterprise Value To Ebitda-5.55
Enterprise Value To Revenue4.11

Immunoprecise Antibodies Current Valuation Indicators

Valuation refers to the process of determining the present value of Immunoprecise Antibodies and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Immunoprecise we look at many different elements of the entity such as Immunoprecise's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Immunoprecise Antibodies' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Immunoprecise Antibodies' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immunoprecise Antibodies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immunoprecise Antibodies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immunoprecise Antibodies' worth.
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.